Oncimmune (LON:ONC) Releases Earnings Results

Oncimmune (LON:ONC) announced its quarterly earnings results on Monday. The company reported GBX (4.72) (($0.06)) EPS for the quarter, Digital Look Earnings reports. Oncimmune had a net margin of 586.08% and a negative return on equity of 760.96%.

Oncimmune Trading Up 5.1 %

Oncimmune stock traded up GBX 0.39 ($0.00) during trading hours on Wednesday, hitting GBX 8.01 ($0.10). The stock had a trading volume of 1,438,537 shares, compared to its average volume of 304,037. The stock has a market cap of £5.94 million, a price-to-earnings ratio of -267.13 and a beta of 1.19. The company has a quick ratio of 0.63, a current ratio of 1.13 and a debt-to-equity ratio of 806.85. The business’s 50 day simple moving average is GBX 13.37 and its 200-day simple moving average is GBX 14.80. Oncimmune has a one year low of GBX 7.50 ($0.09) and a one year high of GBX 31 ($0.39).

Oncimmune Company Profile

Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel.